Prostatic Neoplasms, Castration-ResistantLACOG 1818NCT04962919
Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.
An observational study of Prostatic Neoplasms, Castration-Resistant, run by Latin American Cooperative Oncology Group at 18 sites in Brazil.
Trial summary
Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostatic Neoplasms, Castration-Resistant
- How many people
- 584 participants
- Where
- 18 sitesBrazil
- Study dates
- 14 Jan 2020to 31 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.
Who may be able to join
- Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.
Who cannot join
- Diagnosis of localized or locally advanced or metastatic disease sensitive to castration;
- Patients with medical records filled with incomplete data that make it impossible to evaluate the treatment received.
Trial locations and contacts
18 sites in 1 country.
18 sites in 1 country
Brazil18 sites
Hospital Sírio-Libanês DF
Brasília, Federal District, 70200-730
Hospital de Base do IGESDF - Instituto de Gestão Estratégica em Saúde do Distrito Federal
Brasília, Federal District, 70335-900
Clínica Prognóstica - Centro de Pesquisa Clínica Onconeo
Campo Grande, Mato Grosso do Sul, 79002-061
UOPECCAN - Hospital do Câncer de Cascavel
Cascavel, Santa Catarina, 85806-300
Hospital Napoleão Laureano
João Pessoa, Paraíba, 58013-140
CPO Pucrs
Porto Alegre, Rio Grande do Sul
IMIP - Instituto de Medicina Integral Professor Fernando Figueira
Recife, Pernambuco, 50070-902
ISEP - Instituto Santa Joana de Ensino e Pesquisa (Rede Américas)
Recife, Pernambuco, 52011-000
Ética Pesquisa Clínica
Salvador, Estado de Bahia, 41.950-640
Centro de Estudos e Pesquisas de Hematologia e Oncologia - CEPHO
Santo André, São Paulo, 09060-650
FUNFARME - Fundação Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto, São Paulo, 15090-000
Hospital de Oncologia do Maranhão Dr. Tarquínio Lopes Filho
São Luís, Maranhão, 65015-460
Hospital Santa Marcelina
São Paulo, São Paulo, (11) 2070-6000
BP - A Beneficência Portuguesa de São Paulo
São Paulo, São Paulo, 01.323-030
Irmandade da Santa Casa de Misericórdia de São Paulo - Hospital Central
São Paulo, São Paulo, 01221-010
Sírio Libanês
São Paulo, São Paulo, 01308-050
A.C.Camargo Cancer Center
São Paulo, São Paulo, 01525-001
Centro Paulista de Oncologia
São Paulo, São Paulo
About this study
Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions
- Keywords
- Prostatic Neoplasms
- Medical subject headings
- Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Public institution | Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017 | |
| Private institution | Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil.
Measured: December of 2017
Secondary outcomes (9)
To describe the sociodemographic characteristics of patients with castration-resistant metastatic prostate cancer in Brazil;
Measured: December of 2017
To describe comorbidities of patients with castration-resistant metastatic prostate cancer in Brazil;
Measured: December of 2017
To describe the clinicopathological characteristics of patients with metastatic castration-resistant prostate cancer in Brazil;
Measured: December of 2017
To compare overall survival among patients with castration-resistant metastatic prostate cancer treated in the SUS and in the private network;
Measured: December of 2017
To compare the treatments performed by patients with castration-resistant metastatic prostate cancer in the SUS and in the private network;
Measured: December of 2017
To describe the rates of skeletal-related complications
Measured: December of 2017
To describe the rate of admissions
Measured: December of 2017
To describe the number of lines of treatment that patients have undergone
Measured: December of 2017
To describe the presence or absence of treatments bone-directed
Measured: December of 2017
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2021
- Study start14 Jan 2020
- Primary completion31 Jan 2024
- Study completion31 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostatic Neoplasms, Castration-ResistantStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 584 participants (actual)
Sponsor and investigators
- Lead sponsor
- Latin American Cooperative Oncology Group
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Fernando Cotait Maluf, Principal investigator, Latin American Cooperative Oncology Group
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04962919
- Sponsor's protocol ID
- LACOG 1818
- Acronym
- LACOG 1818
- Status last verified
- Aug 2026
- First submitted
- 24 Jun 2021
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.
- ClinicalTrials.gov ID
- NCT04962919
- Acronym / sponsor ID
- LACOG 1818 / LACOG 1818
- Keywords
- Prostatic Neoplasms
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 584 participants (actual)
- Lead sponsor
- Latin American Cooperative Oncology GroupUniversity, hospital or other
- Study start
- 14 Jan 2020 (actual)
- Primary completion
- 31 Jan 2024 (actual)
- Study completion
- 31 Jan 2024 (actual)
- First posted
- 15 Jul 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Public institution | – | –Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017 |
| Private institution | – | –Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017 |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.
Key inclusion criteria (1 listed)
- Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.
Key exclusion criteria (2 listed)
- Diagnosis of localized or locally advanced or metastatic disease sensitive to castration;
- Patients with medical records filled with incomplete data that make it impossible to evaluate the treatment received.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil.
Time frame: December of 2017
9 secondary outcomes
To describe the sociodemographic characteristics of patients with castration-resistant metastatic prostate cancer in Brazil;
Time frame: December of 2017
To describe comorbidities of patients with castration-resistant metastatic prostate cancer in Brazil;
Time frame: December of 2017
To describe the clinicopathological characteristics of patients with metastatic castration-resistant prostate cancer in Brazil;
Time frame: December of 2017
To compare overall survival among patients with castration-resistant metastatic prostate cancer treated in the SUS and in the private network;
Time frame: December of 2017
To compare the treatments performed by patients with castration-resistant metastatic prostate cancer in the SUS and in the private network;
Time frame: December of 2017
To describe the rates of skeletal-related complications
Time frame: December of 2017
To describe the rate of admissions
Time frame: December of 2017
To describe the number of lines of treatment that patients have undergone
Time frame: December of 2017
To describe the presence or absence of treatments bone-directed
Time frame: December of 2017
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Prostatic Neoplasms, Castration-Resistant
RecruitingPhase 2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingObservational study
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Prostate Cancer, Prostate Adenocarcinoma
Active, not recruitingPhase 2
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
Active, not recruitingPhase 2
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fernando Cotait Maluf principal investigator
Latin American Cooperative Oncology Group
18 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prostatic Neoplasms, Castration-Resistant, run by Latin American Cooperative Oncology Group at 18 sites in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 18 sites in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil. (time frame: December of 2017). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.